A problematic pattern of inhaling volatile substances like solvents, glues, or aerosols, disproportionately affecting younger and lower-income populations.
Medically reviewed by
Dr. Mihaela G.
Inhalant Use Disorder describes a problematic pattern of inhaling volatile substances, including glues, paint thinners, gasoline, and aerosol products, for their intoxicating effects, leading to clinically significant impairment or distress. This category occupies a distinctive and concerning position in this manual: unlike most other substances, inhalants are typically legal, inexpensive, and easily accessible household or industrial products, never intended for this use, making this disorder particularly common among adolescents and younger populations who may have limited access to other substances but ready access to products like glue, spray paint, or cleaning solvents.
What distinguishes inhalant use from most other substance categories in this chapter is the directness and severity of physical organ damage that can result from repeated use; unlike substances that primarily affect the brain’s reward and regulatory systems, inhalants are directly toxic to multiple organ systems, including the brain, heart, liver, and kidneys, through mechanisms largely unrelated to addiction itself.
This is also a category where socioeconomic and demographic patterns are particularly pronounced and clinically relevant; inhalant use disorder disproportionately affects younger adolescents, certain indigenous and marginalized communities, and lower-income populations, often connected to accessibility and limited availability of other substances, a pattern important for understanding both prevention needs and the broader context surrounding this disorder.
Impaired control over use
Using more or for longer than intended, persistent desire or unsuccessful efforts to cut down, and significant time spent obtaining, using, or recovering from effects.
Social and functional impairment
Continued use despite interpersonal or occupational/educational problems, giving up important activities, and recurrent use in physically hazardous situations.
Risky use and craving
Continued use despite knowledge of significant physical or psychological harm, and craving.
Tolerance and withdrawal
Needing increased amounts for the same effect, and, with sustained, heavy use, a recognized though generally milder withdrawal syndrome compared to several other substances in this manual.
Physical signs of use
Chemical odor on breath or clothing, perioral or perinasal rash or irritation (sometimes called “glue sniffer’s rash”), and signs connected to the specific products used.
⋅ Strong craving or urge to use
⋅ Irritability, particularly when use is interrupted
⋅ Emotional blunting connected to sustained, heavy use
⋅ Distress connected to recognizing the extent or consequences of the pattern
⋅ Persistent preoccupation with obtaining or using inhalants
⋅ Cognitive impairment, sometimes significant and potentially lasting, connected to sustained heavy use
⋅ Minimization of the extent or danger of use
⋅ Difficulty concentrating, both during use and as a longer-term effect of repeated exposure
⋅ Chemical odor on breath, clothing, or in personal spaces
⋅ Perioral or perinasal rash or irritation
⋅ Tolerance, requiring more product for the same effect
⋅ Potential lasting organ damage, particularly to the brain, heart, liver, or kidneys with sustained use
⋅ Using more frequently or in greater quantity than intended
⋅ Continued use despite clear social, educational, or health consequences
⋅ Hoarding or hiding inhalant products
⋅ Using in hazardous or isolated situations, increasing risk of serious injury
Inhalant Use Disorder has a 12-month prevalence of approximately 0.02-0.1% among adults, but rates are considerably higher among adolescents, reflecting the accessibility-driven pattern that distinguishes this disorder from most others in this manual.
Risk factors include younger age, particularly early to mid-adolescence, limited access to other substances, certain indigenous and marginalized community contexts where this pattern has been particularly documented, socioeconomic disadvantage, and significant family instability or limited adult supervision.
Comorbidity with other substance use disorders, conduct disorder, and significant family or social adversity is notable, and inhalant use during adolescence sometimes represents an early pattern that, for some, precedes or co-occurs with other substance use as access to other substances increases with age.
Inhalant Use Disorder develops through an interaction of accessibility, neurobiological, and socioeconomic factors, with accessibility playing an unusually prominent, defining role compared to most other substances in this manual.
Direct accessibility and legality of the relevant products is a uniquely significant factor; unlike most substances covered in this manual, inhalants are typically legal household or industrial products, making them accessible to populations, particularly younger adolescents, who may have limited access to alcohol, cannabis, or other substances.
Rapid, intense central nervous system effects from many inhaled substances produce a quick onset of intoxication, contributing to their reinforcing effects despite the considerable toxicity involved, a combination that’s particularly concerning given how young the typical population using these substances often is.
Socioeconomic and community factors play a meaningfully more pronounced role here than with most other substances; significant disadvantage, limited resources, and, in some documented community contexts, intergenerational patterns of use, contribute to elevated risk in specific populations.
Direct, widespread organ toxicity from many inhalant compounds, affecting the brain, heart, liver, and kidneys through mechanisms largely separate from the addictive process itself, means that the harm connected to this disorder often extends well beyond the typical addiction-related concerns seen with other substances.
Inhalant Use Disorder is diagnosed based on a problematic pattern of using a hydrocarbon-based inhalant substance leading to clinically significant impairment or distress, evidenced by at least two of eleven criteria within a 12-month period, mirroring the structure used across substance use disorders: using more or longer than intended, persistent desire or unsuccessful efforts to cut down, significant time spent obtaining/using/recovering, craving, recurrent failure to fulfill role obligations, continued use despite interpersonal problems, giving up important activities, recurrent hazardous use, continued use despite physical/psychological problems, tolerance, and withdrawal. Severity is specified as mild (2-3 criteria), moderate (4-5), or severe (6 or more).
Differential diagnosis requires distinguishing this from occasional, experimental use, particularly common among adolescents, that doesn’t meet this threshold, though given the substantial toxicity involved, even occasional use carries meaningful health risk worth addressing regardless of whether full diagnostic criteria are met. Careful, comprehensive medical evaluation is important given the potential for significant organ involvement, separate from the substance use disorder diagnosis itself.
Treatment for Inhalant Use Disorder requires attention to both the behavioral pattern and the potential physical health consequences of use, given the toxicity involved.
Medical evaluation and monitoring
Given the genuine risk of organ damage, comprehensive medical evaluation, including assessment of neurological, cardiac, liver, and kidney function, is an important foundational component of care, separate from but alongside addressing the substance use pattern itself.
Behavioral therapy
Cognitive-behavioral therapy and family-based approaches, particularly given how often this disorder affects adolescents, addressing both individual triggers and broader family or social context, form the core of behavioral treatment.
Addressing underlying socioeconomic and social factors
Given the disorder’s particularly strong connection to accessibility and socioeconomic context, effective treatment often benefits from attention to broader social support, family stability, and connection to community resources, beyond what’s typically needed for substance use disorders with less pronounced social determinants.
No specific medication approved
There’s no medication specifically approved for inhalant use disorder, making behavioral and social intervention the primary treatment approach.
School and community-based prevention and intervention
Given how frequently this disorder begins in early to mid-adolescence, school and community-based programs, alongside family involvement, play a particularly important role both in prevention and in connecting affected young people to appropriate treatment.
Seek a comprehensive medical evaluation if you’re using inhalants regularly, given the genuine risk of organ damage. This is an important step regardless of where you are in your relationship with use, given how directly toxic many of these substances are.
If you’re a parent or caregiver, take signs of inhalant use seriously and approach the conversation without excessive shame, given how strongly accessibility, rather than necessarily severe underlying pathology, can drive this particular pattern.
Engage with therapy that addresses both your individual triggers and your broader family or social context. Given how significantly social and environmental factors contribute to this disorder, addressing these alongside individual behavior tends to support better outcomes.
Connect with community resources and support, particularly given the socioeconomic factors often involved. Addressing broader stability and support, not just the substance use itself, is often an important part of sustainable change.
Know that even occasional use carries meaningful health risk, given the substances involved. This isn’t necessarily about developing a formal use disorder before taking the risk seriously; the toxicity itself is significant even with limited use.
The prognosis for Inhalant Use Disorder varies considerably depending on the extent of any physical health consequences already present, alongside the success of behavioral and social intervention.
With appropriate, comprehensive treatment, addressing both the behavioral pattern and any physical health consequences, alongside attention to broader social and family context, many people, particularly adolescents reached relatively early, show meaningful improvement.
Sustained, heavy use carries genuine risk of lasting organ damage, including potential cognitive impairment, making early identification and intervention particularly valuable for minimizing long-term physical consequences.
Addressing underlying socioeconomic and family factors, when relevant, is often an important part of supporting lasting change, given how significantly these factors contribute to risk and recovery trajectory for this particular disorder.
Seek evaluation, including comprehensive medical assessment, if inhalant use, particularly by an adolescent, is suspected or confirmed, given the genuine risk of organ damage involved.
Seek support that addresses both individual and family or social factors, given how significantly these contribute to this particular disorder’s development and course.
Seek immediate medical attention for any signs of significant intoxication, confusion, or cardiac symptoms following inhalant use, given the genuine acute medical risks these substances carry.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
Inhalants are typically legal, inexpensive household or industrial products, glues, aerosols, solvents, making them uniquely accessible to younger people who may have limited access to alcohol, cannabis, or other controlled substances. This accessibility-driven pattern distinguishes inhalant use disorder from most other substance use disorders in this manual, and is part of why prevention and early intervention efforts often specifically target this age group.
Yes, this is an important and distinct consideration. Many inhalant compounds are directly toxic to multiple organ systems, including the brain, heart, liver, and kidneys, through mechanisms largely separate from the addictive process itself. This means even occasional or limited use carries meaningful health risk, regardless of whether someone meets full diagnostic criteria for a use disorder.
Treatment typically requires more attention to potential physical organ damage, given the toxicity involved, alongside the standard behavioral and psychological treatment approaches. Given how frequently this disorder affects adolescents and is connected to socioeconomic and family factors, effective treatment also often involves family-based approaches and attention to broader social context and community resources, more so than is typically central to treating some other substance use disorders.
Signs can include a chemical odor on breath or clothing, irritation or rash around the mouth or nose, slurred speech, disorientation, or finding empty containers of products like aerosols, glue, or solvents in unusual places. If these signs are noticed, approaching the situation directly but without excessive shame, and seeking both medical evaluation and appropriate support, is an important next step.
Howard, M. O., Bowen, S. E., Garland, E. L., Perron, B. E., & Vaughn, M. G. (2011). Inhalant use and inhalant use disorders in the United States. Addiction Science & Clinical Practice, 6(1), 18–31. PubMed
Garland, E. L., & Howard, M. O. (2011). Volatile substance misuse: clinical considerations, neuropsychopharmacology and potential role of pharmacotherapy in management. CNS Drugs, 25(2), 143–155. PubMed
Williams, J. F., Storck, M., American Academy of Pediatrics Committee on Substance Abuse, & American Academy of Pediatrics Committee on Native American Child Health. (2007). Inhalant abuse. Pediatrics, 119(5), 1009–1017. PubMed
Perron, B. E., & Howard, M. O. (2009). Adolescent inhalant use, abuse, and dependence. Addiction, 104(7), 1185–1192. PubMed
Filley, C. M., Halliday, W., & Kleinschmidt-DeMasters, B. K. (2004). The effects of toluene on the central nervous system. Journal of Neuropathology & Experimental Neurology, 63(1), 1–12. PubMed
